Rixubis Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improvements in hemophilia diagnosis rates, availability of recombinant factor ix therapies, expansion of specialized hemophilia treatment centers, increased patient education initiatives, supportive reimbursement policies.

The growth in the forecast period can be attributed to expansion of long-acting clotting factor development, increasing demand for personalized hemophilia management, growth of home infusion services, advancements in recombinant manufacturing efficiency, rising focus on reduced bleeding episodes. Major trends in the forecast period include increasing adoption of recombinant clotting factors, rising focus on prophylactic hemophilia care, expansion of home-based infusion therapies, improved treatment adherence programs, growing emphasis on patient quality of life.

The rising incidence of hemophilia is expected to drive growth in the Rixubis market going forward. Hemophilia is a genetic bleeding disorder that impairs the blood’s ability to clot, resulting in prolonged bleeding episodes. Its prevalence is increasing due to advances in diagnostic techniques, improved awareness, and population growth, leading to the identification of more cases globally. Rixubis provides recombinant factor IX therapy to help prevent and manage bleeding episodes, allowing individuals with hemophilia B to maintain better overall health and reduce complications associated with clotting deficiencies. For example, in April 2025, Pfizer, a US-based pharmaceutical company, reported that the UK hemophilia A and B patient population exceeded 11,800 individuals in 2023-2024, highlighting a clinically significant treated population. Therefore, the rising incidence of hemophilia is driving growth in the Rixubis market.

The increasing allocation of healthcare research and development (R&D) funding is expected to further propel the Rixubis market. R&D funding refers to financial resources dedicated to advancing medical research and developing new treatments and technologies. Rising healthcare demands, technological progress, and government initiatives are driving this growth. R&D funding supports the development of Rixubis by enabling clinical trials and enhancing therapeutic options for patients with hemophilia B. For instance, in May 2023, the US Congressional Research Service projected R&D funding to reach $209.7 billion in FY2024, an increase of $8.9 billion (4.4%) from the estimated $200.8 billion in FY2023. Therefore, increasing healthcare R&D funding is driving growth in the Rixubis market.

The growing number of clinical trials is also expected to propel the Rixubis market forward. Clinical trials are structured studies conducted to evaluate the safety, efficacy, and potential side effects of medical treatments, drugs, or devices in humans. An increasing number of trials reflects the growing complexity of healthcare needs, scientific advancements, and expanded medical research. Clinical trials support Rixubis by providing critical evidence on safety, efficacy, and dosing, informing regulatory approvals and guiding healthcare providers in effective treatment delivery. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based trade organization, reported that industry-sponsored clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023, indicating growing R&D activity that supports innovation and generates additional revenue streams for healthcare systems. Therefore, the rising number of clinical trials is driving growth in the Rixubis market.

Major companies operating in the rixubis market are Takeda Pharmaceutical Company.

North America was the largest region in the rixubis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rixubis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rixubis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the rixubis market by increasing costs related to imported bioprocessing equipment, cell culture materials, purification systems, and cold chain distribution. North America and Europe are particularly affected due to reliance on global biomanufacturing supply chains, while emerging markets face higher therapy acquisition costs. These tariffs are contributing to increased treatment expenses for healthcare systems. However, they are also driving localized biologics manufacturing, regional supply diversification, and investments in domestic recombinant protein production capabilities.

The rixubis market research report is one of a series of new reports that provides rixubis market statistics, including rixubis industry global market size, regional shares, competitors with a rixubis market share, detailed rixubis market segments, market trends and opportunities, and any further data you may need to thrive in the rixubis industry. This rixubis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rixubis is a recombinant factor IX therapy used for the treatment and prevention of bleeding episodes in patients with hemophilia B. It replaces the missing or deficient factor IX, helping to control bleeding and improve patients’ quality of life.

The main types of Rixubis include recombinant factor IX and plasma-derived factor IX. Recombinant factor IX is a genetically engineered protein used to treat hemophilia B by supplementing the deficient or absent clotting factor IX. It is indicated for routine prophylaxis, management of bleeding episodes, and peri-operative care, supporting both hemophilia B treatment and surgical procedures. The therapy is used by pediatric, adult, and geriatric patients.

The rixubis market consists of sales of products such as lyophilized powder and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.